Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
MSD to Cut 250 Jobs as It Foresees Portfolio Changes
MSD K.K., the Japan unit of US pharma giant Merck, is to launch a voluntary redundancy program to shed 250 employees in a bid to cope with its changing product portfolios. A MSD spokesperson told Jiho on August 30 that…
To read the full story
Related Article
- Keytruda Boon Aside, MSD Japan Mulls Job Cuts for Sales and Marketing
September 4, 2019
BUSINESS
- Gilead Names Andrew Hexter as Japan President
April 2, 2026
- Human Judgment Still Key in the AI Era, Pharma Leaders Tell New Recruits
April 2, 2026
- Astellas’ Protein Degrader Setidegrasib Enters PIII in US
April 1, 2026
- Pfizer Hails Adult Rollout of Prevenar 20 as “Milestone” for Public Health
April 1, 2026
- Kyorin Exercises Option for BIODOL’s Pain Drug Candidate
April 1, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…